vs
Dorman Products, Inc.（DORM）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $537.9M、Dorman Products, Inc.の約1.4倍）。Revvityの純利益率が高く（12.7% vs 2.1%、差は10.6%）。Revvityの前年同期比売上増加率が高い（5.9% vs 0.8%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $33.5M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 7.1%）
ドーマン・プロダクツは米国の大手アフターマーケット自動車部品メーカーで、1918年に設立され、本社はペンシルベニア州コルマールに所在します。NASDAQに上場しており、ティッカーシンボルはDORMで、長年にわたり多種多様な交換用部品を市場に供給しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
DORM vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $537.9M | $772.1M |
| 純利益 | $11.6M | $98.4M |
| 粗利率 | 42.6% | — |
| 営業利益率 | 5.8% | 14.5% |
| 純利益率 | 2.1% | 12.7% |
| 売上前年比 | 0.8% | 5.9% |
| 純利益前年比 | -78.8% | 3.9% |
| EPS（希薄化後） | $0.38 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $537.9M | $772.1M | ||
| Q3 25 | $543.7M | $698.9M | ||
| Q2 25 | $541.0M | $720.3M | ||
| Q1 25 | $507.7M | $664.8M | ||
| Q4 24 | $533.8M | $729.4M | ||
| Q3 24 | $503.8M | $684.0M | ||
| Q2 24 | $503.0M | $691.7M | ||
| Q1 24 | $468.7M | $649.9M |
| Q4 25 | $11.6M | $98.4M | ||
| Q3 25 | $76.4M | $46.7M | ||
| Q2 25 | $58.7M | $53.9M | ||
| Q1 25 | $57.5M | $42.2M | ||
| Q4 24 | $54.5M | $94.6M | ||
| Q3 24 | $55.3M | $94.4M | ||
| Q2 24 | $47.4M | $55.4M | ||
| Q1 24 | $32.8M | $26.0M |
| Q4 25 | 42.6% | — | ||
| Q3 25 | 44.4% | 53.6% | ||
| Q2 25 | 40.6% | 54.5% | ||
| Q1 25 | 40.9% | 56.5% | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 40.5% | 56.3% | ||
| Q2 24 | 39.6% | 55.7% | ||
| Q1 24 | 38.7% | 54.6% |
| Q4 25 | 5.8% | 14.5% | ||
| Q3 25 | 19.4% | 11.7% | ||
| Q2 25 | 15.2% | 12.6% | ||
| Q1 25 | 15.8% | 10.9% | ||
| Q4 24 | 16.3% | 16.3% | ||
| Q3 24 | 15.7% | 14.3% | ||
| Q2 24 | 14.4% | 12.4% | ||
| Q1 24 | 11.6% | 6.8% |
| Q4 25 | 2.1% | 12.7% | ||
| Q3 25 | 14.1% | 6.7% | ||
| Q2 25 | 10.9% | 7.5% | ||
| Q1 25 | 11.3% | 6.4% | ||
| Q4 24 | 10.2% | 13.0% | ||
| Q3 24 | 11.0% | 13.8% | ||
| Q2 24 | 9.4% | 8.0% | ||
| Q1 24 | 7.0% | 4.0% |
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $2.48 | $0.40 | ||
| Q2 25 | $1.91 | $0.46 | ||
| Q1 25 | $1.87 | $0.35 | ||
| Q4 24 | $1.76 | $0.77 | ||
| Q3 24 | $1.80 | $0.77 | ||
| Q2 24 | $1.53 | $0.45 | ||
| Q1 24 | $1.05 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $49.4M | $919.9M |
| 総負債低いほど良い | $440.6M | — |
| 株主資本純資産 | $1.5B | $7.3B |
| 総資産 | $2.5B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.30× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $49.4M | $919.9M | ||
| Q3 25 | $55.5M | $931.4M | ||
| Q2 25 | $56.8M | $991.8M | ||
| Q1 25 | $60.6M | $1.1B | ||
| Q4 24 | $57.1M | $1.2B | ||
| Q3 24 | $45.1M | $1.2B | ||
| Q2 24 | $47.5M | $2.0B | ||
| Q1 24 | $34.4M | $1.7B |
| Q4 25 | $440.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $468.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
| Q4 25 | $2.5B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.3B | $13.4B | ||
| Q1 24 | $2.2B | $13.4B |
| Q4 25 | 0.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $41.6M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $33.5M | $161.8M |
| FCFマージンFCF / 売上 | 6.2% | 21.0% |
| 設備投資強度設備投資 / 売上 | 1.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 3.60× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $75.7M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $41.6M | $182.0M | ||
| Q3 25 | $12.2M | $138.5M | ||
| Q2 25 | $8.5M | $134.3M | ||
| Q1 25 | $51.2M | $128.2M | ||
| Q4 24 | $71.4M | $174.2M | ||
| Q3 24 | $44.3M | $147.9M | ||
| Q2 24 | $63.3M | $158.6M | ||
| Q1 24 | $52.0M | $147.6M |
| Q4 25 | $33.5M | $161.8M | ||
| Q3 25 | $1.8M | $120.0M | ||
| Q2 25 | $98.0K | $115.5M | ||
| Q1 25 | $40.3M | $112.2M | ||
| Q4 24 | $63.2M | $149.8M | ||
| Q3 24 | $35.7M | $125.6M | ||
| Q2 24 | $51.4M | $136.6M | ||
| Q1 24 | $41.2M | $129.7M |
| Q4 25 | 6.2% | 21.0% | ||
| Q3 25 | 0.3% | 17.2% | ||
| Q2 25 | 0.0% | 16.0% | ||
| Q1 25 | 7.9% | 16.9% | ||
| Q4 24 | 11.8% | 20.5% | ||
| Q3 24 | 7.1% | 18.4% | ||
| Q2 24 | 10.2% | 19.7% | ||
| Q1 24 | 8.8% | 20.0% |
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 2.3% | 2.7% |
| Q4 25 | 3.60× | 1.85× | ||
| Q3 25 | 0.16× | 2.97× | ||
| Q2 25 | 0.15× | 2.49× | ||
| Q1 25 | 0.89× | 3.03× | ||
| Q4 24 | 1.31× | 1.84× | ||
| Q3 24 | 0.80× | 1.57× | ||
| Q2 24 | 1.34× | 2.87× | ||
| Q1 24 | 1.58× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
DORM
| Light Duty | $428.6M | 80% |
| Heavy Duty | $55.8M | 10% |
| Specialty Vehicle | $53.5M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
